Litcius/Paper detail

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Athanassios Argiris, Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker, Scott Gettinger, Megan E. Daly, Bryan A. Faller, Kathy S. Albain, Ronald Yanagihara, Linda L. Garland, Lauren A. Byers, Ding Wang, Marianna Koczywas, Mary W. Redman, Karen Kelly, David R. Gandara

2021Clinical Lung Cancer26 citationsDOIOpen Access PDF

Topics & Concepts

MedicineVeliparibOncologyPlaceboLung cancerInternal medicineStage (stratigraphy)ChemoradiotherapyPhases of clinical researchRandomized controlled trialClinical trialSurgeryCancerPathologyAlternative medicinePolymeraseChemistryPoly ADP ribose polymeraseGeneBiologyPaleontologyBiochemistryPARP inhibition in cancer therapyLung Cancer Research StudiesLung Cancer Treatments and Mutations
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811) | Litcius